BRIM-1, -2 and -3 trials: improved survival with vemurafenib in metastatic melanoma patients with a BRAFV600Emutation
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
BRIM-1, -2 and -3 trials: improved survival with vemurafenib in metastatic melanoma patients with a BRAFV600Emutation
Authors
Keywords
-
Journal
Future Oncology
Volume 8, Issue 5, Pages 499-507
Publisher
Future Medicine Ltd
Online
2012-05-31
DOI
10.2217/fon.12.43
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Final results of E2603: A double-blind, randomized phase III trial comparing carboplatin (C)/paclitaxel (P) with or without sorafenib (S) in metastatic melanoma.
- (2017) K. T. Flaherty et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors.
- (2017) R. Kefford et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and efficacy results from the first-in-human study of the oral MEK 1/2 inhibitor GSK1120212.
- (2017) J. R. Infante et al. JOURNAL OF CLINICAL ONCOLOGY
- A randomized phase II study comparing mFOLFOX-6 combined with axitinib or bevacizumab or both in patients with metastatic colorectal cancer (mCRC).
- (2017) J. R. Infante et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III randomized study of ipilimumab (IPI) plus dacarbazine (DTIC) versus DTIC alone as first-line treatment in patients with unresectable stage III or IV melanoma.
- (2017) J. D. Wolchok et al. JOURNAL OF CLINICAL ONCOLOGY
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
- (2012) Jeffrey A. Sosman et al. NEW ENGLAND JOURNAL OF MEDICINE
- RASMutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
- (2012) Fei Su et al. NEW ENGLAND JOURNAL OF MEDICINE
- KIT as a Therapeutic Target in Metastatic Melanoma
- (2011) Richard D. Carvajal JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboringc-KitMutation or Amplification
- (2011) Jun Guo et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic and Clinicopathologic Associations of OncogenicBRAFin Metastatic Melanoma
- (2011) Georgina V. Long et al. JOURNAL OF CLINICAL ONCOLOGY
- What Is Value in Health Care?
- (2011) NEW ENGLAND JOURNAL OF MEDICINE
- Cancer Statistics, 2010
- (2010) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function
- (2010) A. Boni et al. CANCER RESEARCH
- Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032
- (2010) Jonas N Søndergaard et al. Journal of Translational Medicine
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
- (2010) Cory M. Johannessen et al. NATURE
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- (2010) Ramin Nazarian et al. NATURE
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- (2010) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutations inGNA11in Uveal Melanoma
- (2010) Catherine D. Van Raamsdonk et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas
- (2010) John T. Lee et al. Pigment Cell & Melanoma Research
- Stopping or Reporting Early for Positive Results in Randomized Clinical Trials: The National Cancer Institute Cooperative Group Experience From 1990 to 2005
- (2009) Edward L. Korn et al. JOURNAL OF CLINICAL ONCOLOGY
- Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma
- (2009) Axel Hauschild et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
- (2008) J. Tsai et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search